Cargando…

Histone Deacetylase Inhibitor Suberanilohydroxamic Acid Treatment Reverses Hyposensitivity to γ‐Aminobutyric Acid in the Ventral Tegmental Area During Ethanol Withdrawal

BACKGROUND: The ventral tegmental area (VTA) is important for alcohol‐related reward and reinforcement. Mouse VTA neurons are hyposensitive to γ‐aminobutyric acid (GABA) during ethanol (EtOH) withdrawal, and GABA responsiveness is normalized by in vitro treatment with histone deacetylase inhibitors...

Descripción completa

Detalles Bibliográficos
Autores principales: You, Chang, Vandegrift, Bertha J., Zhang, Huaibo, Lasek, Amy W., Pandey, Subhash C., Brodie, Mark S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214766/
https://www.ncbi.nlm.nih.gov/pubmed/30103280
http://dx.doi.org/10.1111/acer.13870
_version_ 1783368017507254272
author You, Chang
Vandegrift, Bertha J.
Zhang, Huaibo
Lasek, Amy W.
Pandey, Subhash C.
Brodie, Mark S.
author_facet You, Chang
Vandegrift, Bertha J.
Zhang, Huaibo
Lasek, Amy W.
Pandey, Subhash C.
Brodie, Mark S.
author_sort You, Chang
collection PubMed
description BACKGROUND: The ventral tegmental area (VTA) is important for alcohol‐related reward and reinforcement. Mouse VTA neurons are hyposensitive to γ‐aminobutyric acid (GABA) during ethanol (EtOH) withdrawal, and GABA responsiveness is normalized by in vitro treatment with histone deacetylase inhibitors (HDACi). The present study examined the effect of a systemically administered HDACi, suberanilohydroxamic acid (SAHA) on GABA sensitivity, and related molecular changes in VTA neurons during withdrawal after chronic EtOH intake in rats. METHODS: Sprague Dawley male adult rats were fed with Lieber‐DeCarli diet (9% EtOH or control diet) for 16 days. Experimental groups included control diet‐fed and EtOH diet‐fed (0‐ or 24‐hour withdrawal) rats treated with either SAHA or vehicle injection. Single‐unit recordings were used to measure the response of VTA neurons to GABA. Immunohistochemistry was performed to examine levels of HDAC2, acetylated histone H3 lysine 9 (acH3K9), and GABA(A) receptor α1 and α5 subunits in the VTA; quantitative polymerase chain reaction was performed to examine the mRNA levels of HDAC2 and GABA(A) receptor subunits. RESULTS: VTA neurons from the withdrawal group exhibited GABA hyposensitivity. In vivo SAHA treatment 2 hours before sacrifice normalized the sensitivity of VTA neurons to GABA. EtOH withdrawal was associated with increased HDAC2 and decreased acH3K9 protein levels; SAHA treatment normalized acH3K9 levels. Interestingly, no significant change was observed in the mRNA levels of HDAC2. The mRNA levels, but not protein levels, of GABA(A) receptor α1 and α5 subunits were increased during withdrawal. CONCLUSIONS: Withdrawal from chronic EtOH exposure results in a decrease in GABA‐mediated inhibition, and this GABA hyposensitivity is normalized by in vivo SAHA treatment. Disruption of signaling in the VTA produced by alteration of GABA neurotransmission could be 1 neuroadaptive physiological process leading to craving and relapse. These results suggest that HDACi pharmacotherapy with agents like SAHA might be an effective treatment for alcoholism.
format Online
Article
Text
id pubmed-6214766
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62147662018-12-14 Histone Deacetylase Inhibitor Suberanilohydroxamic Acid Treatment Reverses Hyposensitivity to γ‐Aminobutyric Acid in the Ventral Tegmental Area During Ethanol Withdrawal You, Chang Vandegrift, Bertha J. Zhang, Huaibo Lasek, Amy W. Pandey, Subhash C. Brodie, Mark S. Alcohol Clin Exp Res Neuroscience BACKGROUND: The ventral tegmental area (VTA) is important for alcohol‐related reward and reinforcement. Mouse VTA neurons are hyposensitive to γ‐aminobutyric acid (GABA) during ethanol (EtOH) withdrawal, and GABA responsiveness is normalized by in vitro treatment with histone deacetylase inhibitors (HDACi). The present study examined the effect of a systemically administered HDACi, suberanilohydroxamic acid (SAHA) on GABA sensitivity, and related molecular changes in VTA neurons during withdrawal after chronic EtOH intake in rats. METHODS: Sprague Dawley male adult rats were fed with Lieber‐DeCarli diet (9% EtOH or control diet) for 16 days. Experimental groups included control diet‐fed and EtOH diet‐fed (0‐ or 24‐hour withdrawal) rats treated with either SAHA or vehicle injection. Single‐unit recordings were used to measure the response of VTA neurons to GABA. Immunohistochemistry was performed to examine levels of HDAC2, acetylated histone H3 lysine 9 (acH3K9), and GABA(A) receptor α1 and α5 subunits in the VTA; quantitative polymerase chain reaction was performed to examine the mRNA levels of HDAC2 and GABA(A) receptor subunits. RESULTS: VTA neurons from the withdrawal group exhibited GABA hyposensitivity. In vivo SAHA treatment 2 hours before sacrifice normalized the sensitivity of VTA neurons to GABA. EtOH withdrawal was associated with increased HDAC2 and decreased acH3K9 protein levels; SAHA treatment normalized acH3K9 levels. Interestingly, no significant change was observed in the mRNA levels of HDAC2. The mRNA levels, but not protein levels, of GABA(A) receptor α1 and α5 subunits were increased during withdrawal. CONCLUSIONS: Withdrawal from chronic EtOH exposure results in a decrease in GABA‐mediated inhibition, and this GABA hyposensitivity is normalized by in vivo SAHA treatment. Disruption of signaling in the VTA produced by alteration of GABA neurotransmission could be 1 neuroadaptive physiological process leading to craving and relapse. These results suggest that HDACi pharmacotherapy with agents like SAHA might be an effective treatment for alcoholism. John Wiley and Sons Inc. 2018-09-07 2018-11 /pmc/articles/PMC6214766/ /pubmed/30103280 http://dx.doi.org/10.1111/acer.13870 Text en © 2018 The Authors. Alcoholism: Clinical & Experimental Research published by Wiley Periodicals, Inc. on behalf of Research Society on Alcoholism This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Neuroscience
You, Chang
Vandegrift, Bertha J.
Zhang, Huaibo
Lasek, Amy W.
Pandey, Subhash C.
Brodie, Mark S.
Histone Deacetylase Inhibitor Suberanilohydroxamic Acid Treatment Reverses Hyposensitivity to γ‐Aminobutyric Acid in the Ventral Tegmental Area During Ethanol Withdrawal
title Histone Deacetylase Inhibitor Suberanilohydroxamic Acid Treatment Reverses Hyposensitivity to γ‐Aminobutyric Acid in the Ventral Tegmental Area During Ethanol Withdrawal
title_full Histone Deacetylase Inhibitor Suberanilohydroxamic Acid Treatment Reverses Hyposensitivity to γ‐Aminobutyric Acid in the Ventral Tegmental Area During Ethanol Withdrawal
title_fullStr Histone Deacetylase Inhibitor Suberanilohydroxamic Acid Treatment Reverses Hyposensitivity to γ‐Aminobutyric Acid in the Ventral Tegmental Area During Ethanol Withdrawal
title_full_unstemmed Histone Deacetylase Inhibitor Suberanilohydroxamic Acid Treatment Reverses Hyposensitivity to γ‐Aminobutyric Acid in the Ventral Tegmental Area During Ethanol Withdrawal
title_short Histone Deacetylase Inhibitor Suberanilohydroxamic Acid Treatment Reverses Hyposensitivity to γ‐Aminobutyric Acid in the Ventral Tegmental Area During Ethanol Withdrawal
title_sort histone deacetylase inhibitor suberanilohydroxamic acid treatment reverses hyposensitivity to γ‐aminobutyric acid in the ventral tegmental area during ethanol withdrawal
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6214766/
https://www.ncbi.nlm.nih.gov/pubmed/30103280
http://dx.doi.org/10.1111/acer.13870
work_keys_str_mv AT youchang histonedeacetylaseinhibitorsuberanilohydroxamicacidtreatmentreverseshyposensitivitytogaminobutyricacidintheventraltegmentalareaduringethanolwithdrawal
AT vandegriftberthaj histonedeacetylaseinhibitorsuberanilohydroxamicacidtreatmentreverseshyposensitivitytogaminobutyricacidintheventraltegmentalareaduringethanolwithdrawal
AT zhanghuaibo histonedeacetylaseinhibitorsuberanilohydroxamicacidtreatmentreverseshyposensitivitytogaminobutyricacidintheventraltegmentalareaduringethanolwithdrawal
AT lasekamyw histonedeacetylaseinhibitorsuberanilohydroxamicacidtreatmentreverseshyposensitivitytogaminobutyricacidintheventraltegmentalareaduringethanolwithdrawal
AT pandeysubhashc histonedeacetylaseinhibitorsuberanilohydroxamicacidtreatmentreverseshyposensitivitytogaminobutyricacidintheventraltegmentalareaduringethanolwithdrawal
AT brodiemarks histonedeacetylaseinhibitorsuberanilohydroxamicacidtreatmentreverseshyposensitivitytogaminobutyricacidintheventraltegmentalareaduringethanolwithdrawal